MedTrace Logo

An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis

NCT01633372 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2021-08-30

No results posted yet for this study

Summary

This is a study of itacitinib (INCB039110) in patients with myelofibrosis. This study will evaluate safety and efficacy parameters of itacitinib (INCB039110).

Conditions

  • MPN (Myeloproliferative Neoplasms)

Interventions

DRUG

itacitinib

Sponsors & Collaborators

Principal Investigators

  • Albert Assad, MD · Incyte Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-16
Primary Completion
2013-12-31
Completion
2021-06-29

Countries

  • United States
  • Australia
  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01633372 on ClinicalTrials.gov